(December 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today commented on a ruling by the U.S. District Court for the Southern District of New York on preliminary motions in a breach of contract case involving Medinol, Ltd. The Court granted in part and denied in part both Medinol's and Boston Scientific's motions for summary judgment. The Court also dismissed Medinol's claims against the two Boston Scientific officials named in the case.

"As the ruling states, this is essentially a breach of contract case, which alleges 'grandiose estimates of damage' that are unlikely to succeed," said Boston Scientific spokesman Paul Donovan. "Perhaps most significantly, there is nothing in this ruling that interferes with our ability to continue to sell our TAXUS™ Express²™ paclitaxel-eluting coronary stent system."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with competitive offerings, third party intellectual property, litigation and other factors described in the Company's filings with the Securities and Exchange Commission.